CHASKA, Minn., May 22, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization, today announced that Lifecore has granted a restricted stock unit (“RSU”) award with respect to 525,000 shares of its common stock and a performance stock unit (“PSU”) award for up to 1,500,000 shares of its common stock to Paul Josephs, Lifecore’s newly hired President and Chief Executive Officer. The RSU award and PS ...

CHASKA, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced certain incremental liquidity measures and housekeeping matters related to divested businesses through a series of 8-K filings over the past week. James G. Hall, President and Chief Executive Officer of Lifecore, commented, “We believe these incremental liquidity improvements will provide Lifecore wi ...

CHASKA, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced certain incremental liquidity measures and housekeeping matters related to divested businesses through a series of 8-K filings over the past week. James G. Hall, President and Chief Executive Officer of Lifecore, commented, “We believe these incremental liquidity improvements will provide Lifecore wi ...

Lifecore生物医学公司概况 - Lifecore生物医学公司是一家提供高质量创新产品开发和制造解决方案的领先供应商，拥有40多年的优质、安全和符合监管要求的经验，具备支持未来增长的可用产能和先进设施[4][5] - Lifecore是一家全面集成的CDMO，具有高度差异化的开发和灌装/完成注射级制药产品的能力，拥有先进的生产能力和多种杠杆来持续推动长期增长[4][8][9][10] Lifecore生物医学公司发展前景 - Lifecore正在寻求将操作能力增加到2025年的2200万单位，并计划在2027年将理论产能提高到约7000万单位[6] - Lifecore处于强劲增长的有利位置，预期CDMO需求和价值将持续增长，预计2022-2030年注射剂市场年复合增长率为8.7%[15] - Lifecore的产能目标将增加3倍，创造长期增长的机会，2024年预计填充率将超过1100万单位[22] Lifecore生物医学公司产品和服务 - Lifecore是全球领先的透明质酸（HA）制造商，提供研究级HA，支持标准和定制修改选项[12] - Lifecore拓展其蓝筹客户群，提供制药级HA原料和注射剂的强大能力，目前拥有14个商业客户和29个商业产品[16] - Lifecore目前有33个项目处于不同开发阶段，涵盖早期、中期和晚期项目，为14个客户提供29种商业产品[17] - Lifecore现有开发项目包括9个概念验证项目、8个开发项目和16个规模扩大项目，预计可带来1亿至2亿美元的目标收入机会[18] - 目前有68个额外的管道机会正在讨论中，其中7个使用HA，56个可归类为药物，29个是大型制药/医疗器械公司[19] Lifecore生物医学公司财务表现 - Lifecore在商业收入和调整后EBITDA方面具有稳定、可持续的增长历史，2024年预计收入为1.03亿美元[20] - Lifecore的2024财年展望包括收入为1.25亿至1.3亿美元，调整后EBITDA为1.35亿至1.69亿美元，预计将实现当前收入产能的三倍增长[23] - Lifecore部门2023年5月28日的净销售额为103,269,000美元，净利润为5,049,000美元，调整后净销售额为103,269,000美元，调整后净利润为4,882,000美元，调整后EBITDA为14,701,000美元，总调整后EBITDA为7,238,000美元[27][28] Lifecore生物医学公司管理变动 - Paul Josephs将接替Jim Hall担任Lifecore的CEO，拥有超过30年的制药行业经验，将于2024年5月20日上任[25]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended May 28, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from _________ to _________. Commission file number: 000-27446 LIFECORE BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 94-3025618 (State or other jur ...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q4 2023 Results Conference Call August 31, 2023 8:30 AM ET Company Participants Jeff Sonnek - IR-ICR Jim Hall - President, CEO John Morberg - CFO Operator Good morning, and thank you for joining Lifecore's Fiscal 2023 Fourth Quarter Earnings Call. [Operator Instructions]. Now I'd like to turn the call over to Jeff Sonnek, Investor Relations at ICR. Jeff Sonnek Good morning, and thank you for joining us today to discuss Lifecore Biomedical's Fourth Quarter and Full Yea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Quarter Ended February 26, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period for _________ to _________. Commission file number: 000-27446 LIFECORE BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 94 ...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q3 2023 Earnings Conference Call June 1, 2023 8:30 AM ET Company Participants Jim Hall - President John Morberg - CFO Conference Call Participants Operator Good morning, and thank you for joining us today to discuss Lifecore Biomedical's Third Quarter Fiscal 2023 Earnings Results. Hosting the call today from the company are Jim Hall, President and Chief Executive Officer; and John Morberg, Chief Financial Officer. Before we begin today, I'd like to remind everyone of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Quarter Ended November 27, 2022, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period for _________ to _________. Commission file number: 000-27446 LIFECORE BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 94 ...